Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | CLK1 | P49759 | 2/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.30 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3707769 | 0.78 | CYP1A2 (0.53) | CYP1A2CYP2C9 | |
| SCHEMBL15829273 | 0.77 | TNKS (0.38) | CYP1A2CYP2C9DGAT1EIF2AK4 | |
| SCHEMBL23775720 | 0.77 | KDM4E (0.38) | TYRCYP1A2CYP2C9RXRADGAT1 | |
| SCHEMBL13976120 | 0.76 | LMNA (0.39) | CYP1A2CYP2C9RXRADGAT1CLK1 | |
| SCHEMBL22521532 | 0.76 | TGFBR1 (0.41) | CYP1A2CYP2C9RXRADGAT1CLK1 | |
| SCHEMBL22944713 | 0.75 | NPC1 (0.35) | CYP1A2CYP2C9DGAT1CLK1 | |
| SCHEMBL1865755 | 0.75 | MAP3K14 (0.43) | CYP1A2CYP2C9CLK1 | |
| SCHEMBL23511269 | 0.75 | DGAT1 (0.40) | CYP1A2CYP2C9DGAT1CLK1EGLN1 | |
| SCHEMBL3787763 | 0.75 | ADORA2A (0.40) | — | |
| SCHEMBL5100079 | 0.75 | POLB (0.47) | EIF2AK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200055823-A1 | QUINOLONE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2020-02-20 | — | — | US | disclosed |
| US-20190077762-A1 | QUINOLONE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2019-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200055823-A1 | QUINOLONE COMPOUND | HAX1, NQO2, NHERF1 | TYR 2158/4885CYP1A2 252/4885CYP2C9 357/4885 |
| US-20190077762-A1 | QUINOLONE COMPOUND | HAX1, NQO2, NHERF1 | TYR 2127/4885CYP1A2 280/4885CYP2C9 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.